Company / Operating Cash Flow
Pacira BioSciences, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$152.0M
FY2025
5-year range
$70.5M / $189.4M
FY2021-FY2025
Trend
-19.7%
vs FY2024
Sector context
#45 of 216
Health Care
What the data says
Pacira BioSciences, Inc.'s operating cash flow of $152M is higher than 79% of companies in the Health Care sector (FY2025). Operating Cash Flow has fluctuated over the past 10 years, ranging from $18M in FY2019 to $189M in FY2024.
Based on SEC 10-K filings.
$152M in FY2025 with a 5-year CAGR of +25.5%. Top quartile in the Health Care sector.
Remained stable around $152M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +1.5%
- 5-Year CAGR
- +25.5%
- 10-Year CAGR
- -
Sector benchmark
-76.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +25.5%, indicating consistent growth.
- In FY2025, operating cash flow decreased 19.7% year-over-year.
- Ranks #45 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2024.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Negative profit margin: -14.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $152.0M | -19.7% |
| FY2024 | $189.4M | +22.5% |
| FY2023 | $154.6M | +6.5% |
| FY2022 | $145.3M | +106.0% |
| FY2021 | $70.5M | +44.3% |
| FY2020 | $48.9M | +174.8% |
| FY2019 | $17.8M | -46.8% |
| FY2018 | $33.5M | +19.4% |
| FY2017 | $28.0M | -16.2% |
| FY2016 | $33.5M | +19.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026